Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/9/2018
SIETES contiene 92559 citas

 
 
 1 a 20 de 28 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Drugs and their names. Drug Ther Bull 2018;56:marzo. [Ref.ID 102507]
2. Cita con resumen
Anónimo. Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis. Med Lett Drugs Ther 2014;56:10-2. [Ref.ID 97221]
3.
Miselli M. Certolizumab pegol. Informazioni sui Farmaci 2011;35:3-4. [Ref.ID 90528]
4. Cita con resumen
Chang C, Gershwin ME. Drug-induced lupus erythematosus. Incidence, management and prevention. Drug Saf 2011;34:357-74. [Ref.ID 90404]
5. Cita con resumen
Anónimo. Pegloticase (Krystexxa) for treatment of refractory gout. Med Lett Drugs Ther 2011;53:9-10. [Ref.ID 90164]
6. Cita con resumen
Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon F-X, Guilhot F, for the SPIRIT Investigators and France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010;363:2511-21. [Ref.ID 89815]
8.
Anónimo. Certolizumab (Cimzia) for Crohn's disease. Med Lett Drugs Ther 2008;50:81-2. [Ref.ID 84441]
9. Cita con resumen
Dudzinski DM, Kesselheim AS. Scientific and legal viability of follow-on protein drugs. N Engl J Med 2008;358:843-9. [Ref.ID 82210]
10. Cita con resumen
11.Tiene citas relacionadas
Levin NW. The MAXIMA trial. Author's reply. Lancet 2008;371:300. [Ref.ID 82045]
12.Tiene citas relacionadas
Nonoguchi H, Izumi Y, Nakayama Y, Kohda Y, Tomita K. The MAXIMA trial. Lancet 2008;371:299-300. [Ref.ID 82044]
13.Tiene citas relacionadas Cita con resumen
Levin NW, Fishbane S, Valdés Cañedo F, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D, on behalf of the MAXIM study investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370:1415-21. [Ref.ID 81349]
14.Tiene citas relacionadas Cita con resumen
Walker RG, Strippoli GFM. A pegylated epoetin in anaemia of renal disease: non-inferiority for an unvalidated surrogate. Lancet 2007;370:1395-6. [Ref.ID 81346]
15.Tiene citas relacionadas
Lewis JD. Anti-TNF antibodies for Crohn's disease. The editorialist replies. N Engl J Med 2007;357:1662. [Ref.ID 81311]
16.Tiene citas relacionadas
Camilleri M. Anti-TNF antibodies for Crohn's disease. N Engl J Med 2007;357:1662. [Ref.ID 81310]
17.Tiene citas relacionadas
Lewis JD. Anti-TNF antibodies for Crohn's disease - in pursuit of the perfect clinical trial. N Engl J Med 2007;357:296-8. [Ref.ID 80591]
18.Tiene citas relacionadas Cita con resumen
Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, for the PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50. [Ref.ID 80586]
19.Tiene citas relacionadas Cita con resumen
Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, for the PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38. [Ref.ID 80585]
20. Cita con resumen
Anónimo. Roche suspends enrolment in CERA oncology trial. Scrip 2007;3237:20. [Ref.ID 79372]
Seleccionar todas
 
 1 a 20 de 28 siguiente >>